General Information of Drug (ID: DM3Y09Z)

Drug Name
SR-3850 Drug Info
Synonyms Rho kinase inhibitors (hypertension, glaucoma, cancer); Rho kinase inhibitors (hypertension, glaucoma, cancer), Scripps
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
TTD Drug ID
DM3Y09Z

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Belumosudil DM548TK Graft-versus-host disease 4B24 Approved [3]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [4]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [5]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [6]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [6]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [6]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [6]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [6]
PMID28048944-Compound-6 DM5RCBV N. A. N. A. Patented [6]
PMID28048944-Compound-2 DM9ZXOP N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Netarsudil DM0LPI9 Open-angle glaucoma 9C61 Approved [7]
SAR-407899 DMF95KD Diabetic nephropathy GB61.Z Phase 2 [8]
H-1152 DM8XH3S Pulmonary arterial hypertension BB01.0 Phase 2 [9]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [4]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [5]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [6]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [6]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [6]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [6]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [1]
Rho-associated protein kinase 2 (ROCK2) TTGWKQJ ROCK2_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504).
3 Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
6 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
7 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8 The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
9 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.